Hengsai Bio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 7

Hengsai Bio General Information

Description

Developer of personalized dendritic cell tumor vaccines intended to provide new treatment approaches and strategies for relapsed and refractory tumors. The company's vaccines focuses on on the field of tumor immunotherapy and has been developed to treat relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments, enabling healthcare professionals to administer treatments and vaccines with safety, efficiency, and convenience in mind.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Building A1, Number 356 Zhengbo Road, Lingang New Area
  • China Pilot Free Trade Zone
  • Shanghai, 202413
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 4th Floor, Building A1, Number 356 Zhengbo Road, Lingang New Area
  • China Pilot Free Trade Zone
  • Shanghai, 202413
  • China
+86 021

Hengsai Bio Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hengsai Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 30-Dec-2025 Completed Generating Revenue
4. Later Stage VC 10-May-2024 Completed Generating Revenue
3. Later Stage VC 16-Jan-2024 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 27-Nov-2023 $13.8M $18.6M Completed Pre-Clinical Trials
1. Early Stage VC 20-Apr-2022 $4.71M $4.71M Completed Pre-Clinical Trials
To view Hengsai Bio’s complete valuation and funding history, request access »

Hengsai Bio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tasly Capital Corporate Venture Capital Minority
Zhongshan Xiwan Investment Holding Development Venture Capital Minority
CuiHeng Group Corporation Minority
Zhongshan Financial Investment Venture Capital Minority
Bison Capital Financial Holdings Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Hengsai Bio FAQs

  • When was Hengsai Bio founded?

    Hengsai Bio was founded in 2018.

  • Where is Hengsai Bio headquartered?

    Hengsai Bio is headquartered in Shanghai, China.

  • What industry is Hengsai Bio in?

    Hengsai Bio’s primary industry is Drug Discovery.

  • Is Hengsai Bio a private or public company?

    Hengsai Bio is a Private company.

  • What is Hengsai Bio’s current revenue?

    The current revenue for Hengsai Bio is .

  • How much funding has Hengsai Bio raised over time?

    Hengsai Bio has raised $18.6M.

  • Who are Hengsai Bio’s investors?

    Tasly Capital, Zhongshan Xiwan Investment Holding Development, CuiHeng Group, Zhongshan Financial Investment, and Bison Capital Financial Holdings are 5 of 7 investors who have invested in Hengsai Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process